Cargando…

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension

OBJECTIVES: To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period. METHODS: Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergman, Joakim, Burman, Joachim, Bergenheim, Tommy, Svenningsson, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880973/ https://www.ncbi.nlm.nih.gov/pubmed/32901316 http://dx.doi.org/10.1007/s00415-020-10210-0

Ejemplares similares

Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
por: Bergman, Joakim, et al.
Publicado: (2020)

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
por: Svenningsson, Anders, et al.
Publicado: (2015)

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
por: Burman, Joachim, et al.
Publicado: (2023)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)
por: Bonnan, Mickael, et al.
Publicado: (2021)

Inflammatory activity and vitamin D levels in an MS population treated with rituximab
por: Linden, Johan, et al.
Publicado: (2019)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

PATIENTS’ EXPECTATIONS BEFORE INITIATION OF INTRATHECAL BACLOFEN TREATMENT: A LONGITUDINAL STUDY WITH 1-YEAR FOLLOW-UP
por: GUNNARSSON, STINA, et al.
Publicado: (2023)

Onset of secondary progressive MS after long‐term rituximab therapy – a case report
por: von Büdingen, H.‐Christian, et al.
Publicado: (2016)

Safety of long-term intrathecal methotrexate in progressive forms of MS
por: Stark, James W., et al.
Publicado: (2019)

Acute painful lumbosacral paresthesia after intrathecal rituximab
por: Bromberg, J. E. C., et al.
Publicado: (2011)

Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
por: Tjensvoll, Anne Bolette, et al.
Publicado: (2019)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS
por: Oechtering, Johanna, et al.
Publicado: (2022)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
por: Coles, Alasdair J., et al.
Publicado: (2021)

Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS?
por: Weber, Martin S.
Publicado: (2015)

Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry
por: Carlsson, Henrik, et al.
Publicado: (2020)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
por: Bachy, Emmanuel, et al.
Publicado: (2019)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Intrathecal Inflammation in Progressive Multiple Sclerosis
por: Monaco, Salvatore, et al.
Publicado: (2020)

Clinical utility of epidural volume extension following reduced intrathecal doses: a randomized controlled trial()
por: Tyagi, Asha, et al.
Publicado: (2020)

Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing
por: Carlsson, Henrik, et al.
Publicado: (2021)

Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report
por: Balaban, Denis T., et al.
Publicado: (2023)

Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS
por: Duell, Frida, et al.
Publicado: (2020)

Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS
por: Engel, Sinah, et al.
Publicado: (2020)

Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction
por: Jarius, S., et al.
Publicado: (2021)

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022)

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls
por: de Flon, Pierre, et al.
Publicado: (2018)

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden
por: Wickström, Anne, et al.
Publicado: (2015)

Intrathecal Rituximab as a Rescue Therapy in Refractory Pure CSF Positive, Non-Teratomatous Type Anti-NMDAR Encephalitis
por: Krishnan, Parameswaran, et al.
Publicado: (2022)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Off-label use of rituximab in dermatology: pemphigus treatment
por: Bomm, Lislaine, et al.
Publicado: (2013)

Case of Abdominal Wound, with Protrusion and Wound of Small Intestine, the Result of a Stab: Recovery
por: Burman, C. Clark
Publicado: (1884)

Intrathecal corticosteroids might slow Alzheimer’s disease progression
por: Alisky, Joseph Martin
Publicado: (2008)

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
por: Glitza Oliva, Isabella C., et al.
Publicado: (2023)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0g2fi8e7a9p3csr4dqj3sjtoar